Owen O'connor
Experienced in Chronic Lymphocytic Leukemia (CLL)

Dr. Owen O'connor

Oncology
Montefiore Einstein
WPHPA Cancer And Blood Specialists Of New York
2 Longview Avenue, 3rd Floor, 
White Plains, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Chronic Lymphocytic Leukemia (CLL)
Montefiore Einstein
WPHPA Cancer And Blood Specialists Of New York
2 Longview Avenue, 3rd Floor, 
White Plains, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Owen A. O'Connor is internationally renowned for his expertise on the diagnosis and treatment of all forms of lymphoma, with over 25 years of experience in academic medicine. He has invented and pioneered the development of several first in class drugs for the treatment of lymphoma, including one he co-invented for T-cell lymphoma which has now been approved in over 35 countries around the world. He has held several prestigious leadership positions at the major cancer centers in New York City, including Memorial Sloan Kettering Cancer Center, New York University Medical Center, and Cornell and Columbia University Medical Centers.

Dr. O'connor is rated as an Experienced provider by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Anaplastic Large Cell Lymphoma.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 2 clinical trials in the study of Chronic Lymphocytic Leukemia (CLL).

Graduate Institution
University Of Medicine And Denistry Of New Jersey
Residency
New York Hospital Presbyterian-Cornell Medical Ctr
Specialties
Oncology
Licenses
Internal Medicine in NY
Fellowships
Memorial Sloan-Kettering Cancer Center
Hospital Affiliations
White Plains Hospital Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WPHPA Cancer and Blood Specialists of New York
2 Longview Avenue, 3rd Floor, White Plains, NY 10601
Call: 914-849-7630
Other Locations
White Plains Hospital Center for Cancer Care, Lowenthal Infusion Center
2-4 Longview Avenue, 3rd Floor, White Plains, NY 10601
Call: 914-849-7633

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Enrollment Status: Recruiting
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drugs: Durvalumab, Pralatrexate, Romidepsin, Azacitidine
Study Phase: Phase 1/Phase 2
Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies
Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies
Enrollment Status: Terminated
Publish Date: August 22, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

129 Total Publications

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.
Journal: British journal of haematology
Published: February 12, 2025
View All 129 Publications
Similar Doctors
Elite in Chronic Lymphocytic Leukemia (CLL)
Dr. Nicole Lamanna
Oncology | Hematology
Elite in Chronic Lymphocytic Leukemia (CLL)
Dr. Nicole Lamanna
Oncology | Hematology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (15.7 miles away)
212-305-9876
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nicole Lamanna is an Oncologist and a Hematologist in New York, New York. Dr. Lamanna is rated as an Elite provider by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Gastrostomy.

Richard R. Furman
Elite in Chronic Lymphocytic Leukemia (CLL)
Dr. Richard R. Furman
Hematology | Oncology
Elite in Chronic Lymphocytic Leukemia (CLL)
Dr. Richard R. Furman
Hematology | Oncology

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (20.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Furman is a Hematologist and an Oncologist in New York, New York. Dr. Furman is rated as an Elite provider by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Lymphadenectomy.

Elite in Chronic Lymphocytic Leukemia (CLL)
Dr. Andrew D. Zelenetz
Oncology
Elite in Chronic Lymphocytic Leukemia (CLL)
Dr. Andrew D. Zelenetz
Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (20.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Zelenetz is an Oncologist in New York, New York. Dr. Zelenetz is rated as an Elite provider by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Diffuse Large B-Cell Lymphoma (DLBCL).

VIEW MORE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. O'connor's expertise for a condition
ConditionClose
  • Elite
  • Non-Hodgkin Lymphoma
    Dr. O'connor is
    Elite
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Peripheral T-Cell Lymphoma
    Dr. O'connor is
    Elite
    . Learn about Peripheral T-Cell Lymphoma.
    See more Peripheral T-Cell Lymphoma experts
  • T-Cell Lymphoma
    Dr. O'connor is
    Elite
    . Learn about T-Cell Lymphoma.
    See more T-Cell Lymphoma experts
  • Distinguished
  • Anaplastic Large Cell Lymphoma
    Dr. O'connor is
    Distinguished
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • B-Cell Lymphoma
    Dr. O'connor is
    Distinguished
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Gastric Lymphoma
    Dr. O'connor is
    Distinguished
    . Learn about Gastric Lymphoma.
    See more Gastric Lymphoma experts
  • Advanced
  • Angioimmunoblastic T-cell Lymphoma
    Dr. O'connor is
    Advanced
    . Learn about Angioimmunoblastic T-cell Lymphoma.
    See more Angioimmunoblastic T-cell Lymphoma experts
  • Cutaneous T-Cell Lymphoma (CTCL)
    Dr. O'connor is
    Advanced
    . Learn about Cutaneous T-Cell Lymphoma (CTCL).
    See more Cutaneous T-Cell Lymphoma (CTCL) experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. O'connor is
    Advanced
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
  • Follicular Lymphoma
    Dr. O'connor is
    Advanced
    . Learn about Follicular Lymphoma.
    See more Follicular Lymphoma experts
  • Hodgkin Lymphoma
    Dr. O'connor is
    Advanced
    . Learn about Hodgkin Lymphoma.
    See more Hodgkin Lymphoma experts
  • Mantle Cell Lymphoma (MCL)
    Dr. O'connor is
    Advanced
    . Learn about Mantle Cell Lymphoma (MCL).
    See more Mantle Cell Lymphoma (MCL) experts
View All 8 Advanced Conditions
  • Experienced
  • Agranulocytosis
    Dr. O'connor is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Burkitt Lymphoma
    Dr. O'connor is
    Experienced
    . Learn about Burkitt Lymphoma.
    See more Burkitt Lymphoma experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. O'connor is
    Experienced
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Chronic Familial Neutropenia
    Dr. O'connor is
    Experienced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. O'connor is
    Experienced
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Classical Hodgkin Lymphoma
    Dr. O'connor is
    Experienced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.